Response to Lithium Response

Response
TO LITHIUM NETWORK

COVID-19

The ongoing COVID-19 pandemic and national restrictions in the participating countries impact the R-LiNK project. Indeed, several activities cannot be performed in this context. The sponsor (Assistance Publique – Hôpitaux de Paris, France) and the coordinator decided to define a specific procedure for the inclusion of a patient during this period (contact with the coordinator and the sponsor before inclusion). This procedure is in place until further notice. All activities that are not disturbed by the COVID-19 pandemic can continue without limitation. We hope to be able to resume the recruitment again as soon as possible. Take care of you and your beloved.

Inclusion of R-Link’s first patient

We are proud to announce that we have included our first patient on the 10th January 2020 in Dresden, Germany

Latest publications from the R-LiNK initiative

Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative.

by Scott et al. International Journal of Bipolar Disorders

Latest news from R-LiNK

R-Link is a multinational study funded by the European Union’s Horizon 2020 Research and Innovation programme. R-Link involves eight European countries including France, United Kingdom, Denmark, Spain, Norway, Sweden, Germany and Italy.

R-LiNK 1st Annual meeting

The R-LiNK project NewsR-LiNK 1st Annual meetingMarch 28-29, 2019R-Link partners met in Gothenburg for the 1st Annual meeting. It was the opportunity to review the progress of the project and discuss the next steps, in presence of members of the External Advisory…

R-LiNK at RCPsych IC 2019

The International Congress of the Royal College of Psychiatrists is one of the major meetings in the UK (attracting up to 3500 delegates) and this year, R-LiNK was well represented. Dr Squarcina, Dr Boumezbeur and Dr Cousins presented a symposium on the imaging work packages…

European Commission

Primary Goals

Bipolar disorder (BD) is a highly prevalent mental disorder and a leading cause of suicide. Lithium is the primary pharmacological treatment for the prevention of new bipolar disorder episodes or relapses.

Collaborative Research Project

Summary of the project

Optimizing response to lithium treatment through personalized evaluation of individuals with bipolar I disorder: the R-LiNK initiative

This project has received funding from The European Union’s Horizon 2020 Research and Innovation programme Under Grant Agreement N° 754907

Prof. Frank Bellivier, MD, PhD

Department of Psychiatry and Addiction Medicine - Expert Centres Paris Diderot University
INSERM UMR-S1144
frank.bellivier@inserm.fr
Hôpital Fernand Widal 200, rue du Faubourg Saint-Denis 75475 Paris Cedex10. France
Tel Office: +33 1 40 05 42 25 / Tel Assistant: +33 1 40 05 48 69

risus. tempus elit. neque. massa felis ut